2023-07-16-世界卫生组织-Immunization_Lithuania_2023_country_profile_16页_334kb

Summary of WHO and UNICEF Immunization Coverage Estimates for Lithuania (2022 Revision)

Overview

• This report details WHO and UNICEF's joint estimates of national immunization coverage for Lithuania for the 2022 revision, published on July 1, 2023. Estimates are based on data from member states, surveys, administrative records, and recalculation using an independent denominator, with varying quality.

Key Vaccines and Coverage Trends

• BCG: Coverage remained consistently above 98% since 2011, based on administrative data, with high confidence (GoC = •••).
• DTP1, DTP3, Pol3, IPV1, MCV1, MCV2, HepB3, Hib3: Coverage ranged between 90% and 98% across vaccines, showing stability or slight declines in recent years. For example, DTP1 fluctuated around 95-97%, and Pol3 stayed between 90-94%. GoC was generally •• or •••, but recent data saw decline warnings (GoC = ••• with D- challenge indicating data issues).
• HepBB: Coverage was high (95-97%), though interpolated estimates in some years indicated variability. No reliable survey data available within 5 years.
• RotaC and PcV3: Newer vaccines; Rotavirus coverage started in 2018 at ~45%, climbing slowly; Pneumococcal conjugate vaccine (PcV3) introduced in 2014, with coverage around 82% by 2022.
• RCV1 and MCV2: Coverage for Rubella-containing vaccine was estimated based on MCV data rather than direct reporting, with overall similarity to measles coverage.

Data Sources and Confidence

• Estimates primarily use reported administrative data and survey adjustments, recalculated with UN Population Prospects data.
• Grade of Confidence (GoC):
  • •••: High confidence, supported by multiple reliable sources (e.g., BCG, HepBB initial years).
  • ••: Somewhat confident, not fully supported by surveys (e.g., DTP3, Pol3).
  • No accepted empirical data or low confidence marked with D- challenges (e.g., HepBB recent years, declining target groups).

Challenges and Methodology

• No nationally representative surveys within the last 5 years for many vaccines; WHO/UNICEF recommend high-quality surveys.
• Target population denominator declines (10-16% some years) led to estimate challenges for several vaccines, potentially indicating data reliability issues.
• All estimates use caution due to varying data quality, lack of confidence intervals, and potential biases.

Conclusion

Lithuania maintains high immunization coverage for core vaccines (e.g., >90% for DTP, Pol3, HepBB), but some recent declines require monitoring. Newer vaccines show increasing uptake, with recommendations for better data collection for accurate future assessments.